Drug Profile
Research programme: cell movement activators - Pharmaxon
Alternative Names: Cell mobility activators - Pharmaxon; Polysialyl neural cell adhesion molecule mimotope; PR-21C; PR-21S; PSA-NCAM mimotopeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CNRS; Schafer-N; Universite de la Mediterranee; University Medical Center Hamburg-Eppendorf
- Class
- Mechanism of Action Cell movement activators; Polysialyl neural cell adhesion molecule agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Mild cognitive impairment; Spinal cord injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in France
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in France
- 16 Jul 2016 No recent reports of development identified for research development in Mild-cognitive-impairment in France